151 related articles for article (PubMed ID: 16146348)
1. Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate.
Blakesley VA
AAPS J; 2005 Mar; 7(1):E42-6. PubMed ID: 16146348
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence studies for levothyroxine.
Bolton S
AAPS J; 2005 Mar; 7(1):E47-53. PubMed ID: 16146349
[TBL] [Abstract][Full Text] [Related]
3. New questions regarding bioequivalence of levothyroxine preparations: a clinician's response.
Green WL
AAPS J; 2005 Mar; 7(1):E54-8. PubMed ID: 16146330
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.
Dong BJ; Hauck WW; Gambertoglio JG; Gee L; White JR; Bubp JL; Greenspan FS
JAMA; 1997 Apr; 277(15):1205-13. PubMed ID: 9103344
[TBL] [Abstract][Full Text] [Related]
5. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?
Blakesley V; Awni W; Locke C; Ludden T; Granneman GR; Braverman LE
Thyroid; 2004 Mar; 14(3):191-200. PubMed ID: 15072701
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
[TBL] [Abstract][Full Text] [Related]
7. Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism.
Carswell JM; Gordon JH; Popovsky E; Hale A; Brown RS
J Clin Endocrinol Metab; 2013 Feb; 98(2):610-7. PubMed ID: 23264396
[TBL] [Abstract][Full Text] [Related]
8. Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution.
Benvenga S; Carlé A
Adv Ther; 2019 Sep; 36(Suppl 2):59-71. PubMed ID: 31485974
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of thyroid preparations: the final word?
Gibaldi M
AAPS J; 2005; 7(1):E59-60. PubMed ID: 16493834
[No Abstract] [Full Text] [Related]
10. Levothyroxine Bioequivalence Study and Its Narrow Therapeutic Index: Comparative Bioavailability Results Between Two Formulations Available in Latin America.
Bertoncini CW; Palacios MJC; Fritz MC; Rodriguez MP; Acevedo C; Hunzicker GA; Dominguez MC; Arbeláez I
Adv Ther; 2023 Apr; 40(4):1644-1654. PubMed ID: 36422808
[TBL] [Abstract][Full Text] [Related]
11. Levothyroxine sodium tablets: chemical equivalence and bioequivalence.
Curry SH; Gums JG; Williams LL; Curry RW; Wolfson BB
Drug Intell Clin Pharm; 1988; 22(7-8):589-91. PubMed ID: 3046889
[TBL] [Abstract][Full Text] [Related]
12. Generic substitution: issues for problematic drugs.
Henderson JD; Esham RH
South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
[TBL] [Abstract][Full Text] [Related]
13. An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability.
Kocic I; Homsek I; Dacevic M; Parojcic J; Miljkovic B
AAPS PharmSciTech; 2011 Sep; 12(3):938-48. PubMed ID: 21748540
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence of two commercially available levothyroxine-Na preparations in athyreotic patients.
Gottwald R; Lorkowski G; Petersen G; Schnitzler M; Lücker PW
Methods Find Exp Clin Pharmacol; 1994 Nov; 16(9):645-50. PubMed ID: 7746026
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of generic preparations of levothyroxine.
Toft A
Clin Endocrinol (Oxf); 2009 Oct; 71(4):603; author reply 603-4. PubMed ID: 19508682
[No Abstract] [Full Text] [Related]
16. Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution.
Koytchev R; Lauschner R
Arzneimittelforschung; 2004; 54(10):680-4. PubMed ID: 15553108
[TBL] [Abstract][Full Text] [Related]
17. A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers.
Yannovits N; Zintzaras E; Pouli A; Koukoulis G; Lyberi S; Savari E; Potamianos S; Triposkiadis F; Stefanidis I; Zartaloudis E; Benakis A
Eur J Drug Metab Pharmacokinet; 2006; 31(2):73-8. PubMed ID: 16898074
[TBL] [Abstract][Full Text] [Related]
18. Levothyroxine dosage and the limitations of current bioequivalence standards.
Hennessey JV
Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756
[No Abstract] [Full Text] [Related]
19. When Bioequivalence in Healthy Volunteers May not Translate to Bioequivalence in Patients: Differential Effects of Increased Gastric pH on the Pharmacokinetics of Levothyroxine Capsules and Tablets.
Seng Yue C; Benvenga S; Scarsi C; Loprete L; Ducharme MP
J Pharm Pharm Sci; 2015; 18(5):844-55. PubMed ID: 26670370
[TBL] [Abstract][Full Text] [Related]
20. New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials.
Gottwald-Hostalek U; Uhl W; Wolna P; Kahaly GJ
Curr Med Res Opin; 2017 Feb; 33(2):169-174. PubMed ID: 27718637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
